title: Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
abstract: The differential overexpression of self-antigens on tumor cells is a prime feature of malignant transformation. Thomsen-Friedenreich (TF), a core disaccharide of O-glycosylated complex glycoproteins, is one of many "self" antigens expressed on malignantly transformed cells that has served as a target for immune recognition and attack. Previously, we conducted clinical trials with a series of synthetic glycolipid, peptide and carbohydrate antigens conjugated to the immunological carrier keyhole limpet hemocyanin (KLH) mixed with the immunological saponin adjuvant, QS21. These trials resulted in the generation of high-titer IgM and IgG antibody responses specific for the individual antigens, and, in several cases, the capacity of those antibodies to mediate complement lysis. Four groups of five patients who had evidence of a biochemical relapse defined as rising prostate-specific antigens (PSAs) following primary therapy for prostate cancer with either prostatectomy or radiation were treated with escalating doses of 1, 3, 10 and 30 microg of synthetic TF in a clustered formation (c) which was conjugated to KLH and given with 100 microg of QS21. Patients received a total of five subcutaneous vaccines over 6 months and were monitored expectantly with scans every 3-4 months. Serum samples were obtained at weeks 1, 2, 3, 7, 9, 13, 19, 26, 50 and every 3 months. Antibody titers were monitored by ELISA and antibody binding to the cell surface of prostate cell lines was performed by flow cytometry. Complement-dependent cytotoxicity was performed on selected patients. Twenty evaluable patients were accrued to the study, of whom only one did not receive all six vaccinations. All patients developed maximum IgM and IgG antibody titers by week 9. The median IgM antibody titer by week 7 was 1/1,280 at 10 microg, 1/320 at 30 microg, 1/1,280 at 3 microg and 1/1,280 at 1 microg dose groups. The IgM titers from all groups remained greater than 1/320 by week 32 and beyond through week 50. We report here the results of a dose-escalating trial of a TF(c)-KLH conjugate vaccine in patients in the clinical state of a rising PSA in the absence of radiographic disease. For the first time, a synthetically made TF trimer or cluster (c) was made with three TF disaccharides attached to three sequential threonines on a peptide backbone. TF(c) doses of 1, 3, 10 and 30 microg were conjugated to KLH and administered with QS21. All doses induced high-titer IgM and IgG antibodies against TF. Unlike our findings in previous dose-escalating phase I trials, there did not appear to be increased antibody production with increasing doses of vaccine; higher titers of IgM and IgG antibodies developed at the lowest dose level (1 microg). An anti-tumor effect in the form of a change in post-treatment versus pretreatment logPSA slopes was also observed. The results justify the inclusion of TF(c) at a dose of 1 microg as a relevant antigenic target in a multivalent phase II vaccine trial in patients in the high-risk minimal disease state.
authors.affiliation: Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. slovins@mskcc.org
authors.forename: Susan F
authors.initials: SF
authors.lastname: Slovin
authors.forename: Govind
authors.initials: G
authors.lastname: Ragupathi
authors.forename: Cristina
authors.initials: C
authors.lastname: Musselli
authors.forename: Celina
authors.initials: C
authors.lastname: Fernandez
authors.forename: Meghan
authors.initials: M
authors.lastname: Diani
authors.forename: David
authors.initials: D
authors.lastname: Verbel
authors.forename: Samuel
authors.initials: S
authors.lastname: Danishefsky
authors.forename: Philip
authors.initials: P
authors.lastname: Livingston
authors.forename: Howard I
authors.initials: HI
authors.lastname: Scher
mesh_terms: D000276:Adjuvants, Immunologic; D000368:Aged; D000951:Antigens, Neoplasm / Q000276:immunology*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006433:Hemocyanins / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D012503:Saponins / Q000276:immunology*; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D019496:Cancer Vaccines; D012503:Saponins; D018074:Vaccines, Conjugate; C016467:Thomsen-Friedenreich antigen; C078785:saponin QA-21V1; D006433:Hemocyanins; D017430:Prostate-Specific Antigen; C032808:keyhole-limpet hemocyanin
references.citation: J Clin Pathol. 1998 Aug;51(8):588-92
references.pmid: 9828816
references.citation: Angew Chem Int Ed Engl. 1999 Feb 15;38(4):563-566
references.pmid: 29711780
references.citation: J Clin Oncol. 2003 Dec 1;21(23):4292-8
references.pmid: 14645418
references.citation: Cancer Res. 1999 Oct 15;59(20):5160-8
references.pmid: 10537292
references.citation: Cancer Detect Prev. 1995;19(2):173-82
references.pmid: 7750105
references.citation: J Clin Oncol. 2004 Feb 1;22(3):537-56
references.pmid: 14752077
references.citation: Proc Natl Acad Sci U S A. 1999 May 11;96(10):5710-5
references.pmid: 10318949
references.citation: Cancer. 2000 Apr 1;88(7):1536-43
references.pmid: 10738210
references.citation: Int J Cancer. 1999 Feb 19;84(1):1-5
references.pmid: 9988223
references.citation: Clin Cancer Res. 2000 Mar;6(3):874-9
references.pmid: 10741710
references.citation: Histopathology. 1994 Dec;25(6):537-43
references.pmid: 7698730
references.citation: Hum Pathol. 1996 Dec;27(12):1341-7
references.pmid: 8958309
references.citation: Cancer Res. 2001 Jun 15;61(12):4851-7
references.pmid: 11406562
references.citation: Clin Cancer Res. 2000 May;6(5):1693-701
references.pmid: 10815887
references.citation: J Clin Oncol. 2000 Dec 1;18(23):3894-903
references.pmid: 11099318
references.citation: Int J Cancer. 2000 Jul 1;87(1):79-85
references.pmid: 10861456
references.citation: Cancer Res. 1995 Aug 1;55(15):3364-8
references.pmid: 7614472
references.citation: Cancer Immunol Immunother. 1995 Sep;41(3):185-92
references.pmid: 7553688